Influence of severe heart failure to function and molecular biological parameters of catabolism in the human Diaphragm and peripheral skeletal muscle

Influence of severe heart failure to function and molecular biological parameters of catabolism in the human Diaphragm and peripheral skeletal muscle - LIPAMUS-HF

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00009848

Enrollment

Registered

2016-01-05

Start date

2016-01-12

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I50.14

Interventions

Group 1: Patients (age 40 – 70 years) with severe therapy-refractory heart failure caused by ischemic or dilatative myocardiopahty with indication for LVAD therapy study-specific investigations - Qu

Eligibility

Sex/Gender

All

Age

40 Years to 70 Years

Inclusion criteria

Inclusion criteria: inclusion criteria Group A: - age 40 – 70 years - Restricted left ventricular pump function LVEF> 35% on the basis of ischemic cardiomyopathy (ICM) and restricted resting cardiac output (CI> 2.4 L / min / m²) - or restricted maximal oxygen uptake (VO2max> 17 ml / min / m²) - Duration of heart failure> 1 year - Maximum of individual heart failure therapy - Heart team decision to LVAD Implantation inclusion criteria Group B: - age 40 – 70 years - Restricted left ventricular pump function LVEF> 35% on the basis of dilatiative cardiomyopathy (DCM) and restricted resting cardiac output (CI> 2.4 L / min / m²) - or restricted maximal oxygen uptake (VO2max> 17 ml / min / m²) - Duration of heart failure> 1 year - Maximum of individual heart failure therapy - Heart team decision to LVAD Implantation inclusion criteria Group C: - age 40 - 70 years - coronary heart disease with indication for elective, coronary artery bypass surgery - normal LV pumping function LVEF> 50% - stable clinical situation (no cardiac decompensation within the last 6 months)

Exclusion criteria

Exclusion criteria: · Mechanical ventilation within the last 3 months · FEV1 70 years · Pregnancy

Design outcomes

Primary

Measure	Time frame
Expression of catabolic E3 ligase MuRF1 at the time of sampling	—

Secondary

Measure	Time frame
in vitro measurements of the muscle protein (poly ubiquitination of proteins, the proteasome activity, fiber typing in the muscle samples and Measurement of the force development of individual muscle fibers)	—

Countries

Germany

Contacts

Public ContactNorman Mangner

Herzzentrum Leipzig GmbHUniversitätsklinik für Kardiologie

norman.mangner@helios-kliniken.de0341 865 1587

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026